{"id":"873","post_author":null,"post_date":null,"post_date_gmt":null,"post_content":null,"post_title":"InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar)","post_excerpt":"This non\u2011therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ocrelizumab, making it ideal for research use. Ocrelizumab is a humanized IgG1 monoclonal antibody that specifically targets CD20, a surface antigen expressed on pre-B and mature B cells but absent on stem cells and plasma cells. CD20 plays a key role in B cell activation and proliferation. By binding to CD20, Ocrelizumab mediates B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This Ocrelizumab biosimilar is well suited for investigating B cell\u2013mediated mechanisms in autoimmunity, neuroinflammation, and hematologic malignancies, as well as for exploring therapeutic B cell depletion strategies.","post_status":"publish","comment_status":null,"ping_status":null,"post_password":null,"post_name":"invivosim-anti-human-cd20-ocrelizumab-biosimilar-sim0090","to_ping":null,"pinged":null,"post_modified":null,"post_modified_gmt":null,"post_content_filtered":null,"post_parent":null,"guid":null,"menu_order":null,"post_type":null,"post_mime_type":null,"comment_count":null,"filter":null,"sku":"SIM0090","path":"\/product\/invivosim-anti-human-cd20-ocrelizumab-biosimilar-sim0090\/","image":"https:\/\/pneuma.bioxcell.com\/Media\/Products\/bioxcell-sim0090-invivosim-anti-human-cd20-ocrelizumab-biosimilar.png","brand_id":null,"brand_name":null,"brand_slug":null,"brand_description":null,"isotype":"Human IgG1, \u03ba","immunogen":"Human CD20","reported_applications":"In vivo functional assays\nin vitro functional assays\nFlow cytometry\nELISA","aggregation":"<5%\nDetermined by SEC","formulation":"pH 7.0\nContains no stabilizers or preservatives","murine_pathogen_tests":"Mouse Norovirus: Negative\nMouse Parvovirus: Negative\nMouse Minute Virus: Negative\nMouse Hepatitis Virus: Negative\nReovirus Screen: Negative\nLymphocytic Choriomeningitis virus: Negative\nLactate Dehydrogenase-Elevating Virus: Negative\nMouse Rotavirus: Negative\nTheiler's Murine Encephalomyelitis: Negative\nEctromelia\/Mousepox Virus: Negative\nHantavirus: Negative\nPolyoma Virus: Negative\nMouse Adenovirus: Negative\nSendai Virus: Negative\nMycoplasma Pulmonis: Negative\nPneumonia Virus of Mice: Negative\nMouse Cytomegalovirus: Negative\nK Virus: Negative","human_pathogen_tests":"","toxicity_test_results":null,"endotoxin":"<ul><li>\u22640.5EU\/mg (\u22640.0005EU\/\u03bcg)<\/li><li>Determined by LAL gel clotting assay<\/li><\/ul>","purity":"<ul><li>\u226595%<\/li><li>Determined by SDS-PAGE<\/li><\/ul>","sterility":"0.2 \u03bcm filtration","production":"Purified from cell culture supernatant in an animal-free facility","purification":"Protein A","composition":null,"volume":null,"concentration":null,"molecular_weight":"150 kDa","storage":"The antibody solution should be stored at the stock concentration at 4\u00b0C. Do not freeze.","rrid":"","recommended_isotype_control":"<a href=\"\/product\/\">RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme<\/a>","recommended_dilution_buffer":"<a href=\"\/product\/\">InVivoPure pH 7.0 Dilution Buffer<\/a>","clone":"Ocrelizumab","technical_data_sheet":"https:\/\/pneuma.bioxcell.com\/api\/v1\/products\/certificate-of-analysis\/SIM0090\/0\/0\/0?apikey=23D50188E6F74755AFFBF95BD41B140B","western_blot_image":null,"new_product_image":null,"product_references":null,"display_pubmed_logo":null,"modified":"2026-03-18 02:10:05","active":"Y"}

InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar)

Clone	Catalog #	Category
Ocrelizumab	SIM0090

USD 235 - USD 8140

Technical Data Sheet

SDS Sheet

About InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar)

This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ocrelizumab, making it ideal for research use. Ocrelizumab is a humanized IgG1 monoclonal antibody that specifically targets CD20, a surface antigen expressed on pre-B and mature B cells but absent on stem cells and plasma cells. CD20 plays a key role in B cell activation and proliferation. By binding to CD20, Ocrelizumab mediates B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). This Ocrelizumab biosimilar is well suited for investigating B cell–mediated mechanisms in autoimmunity, neuroinflammation, and hematologic malignancies, as well as for exploring therapeutic B cell depletion strategies.

InVivoSIM anti-human CD20 (Ocrelizumab Biosimilar) Specifications

Isotype	Human IgG1, κ
Recommended Isotype Control(s)	RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer	InVivoPure pH 7.0 Dilution Buffer
Immunogen	Human CD20
Reported Applications	In vivo functional assays in vitro functional assays Flow cytometry ELISA
Formulation	pH 7.0 Contains no stabilizers or preservatives
Endotoxin	≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay
Aggregation	<5% Determined by SEC
Purity	≥95% Determined by SDS-PAGE
Sterility	0.2 μm filtration
Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A
Molecular Weight	150 kDa
Storage	The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.